Despite the promise of PI3K inhibitors, there are several challenges in their clinical application. One major challenge is the development of resistance to PI3K inhibitors. Cancer cells can activate alternative signaling pathways or acquire additional mutations that bypass the inhibited PI3K pathway. Another challenge is the toxicity associated with PI3K inhibitors, as PI3K signaling is also important for normal cellular functions. Therefore, balancing efficacy and toxicity is crucial in the development of PI3K-targeted therapies.
